Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

Fig. 3

Comparisons of 1-year Progression Free Survival (PFS) of T-DM1 in 2nd line between trastuzumab pertuzumab pre-treated population and EMILIA trial population. The left part of the figure shows the studies included in the analysis with their corresponding rate difference, standard error, lower and upper limits, z-value and p-value while the right part of the figure show a forest plot of the data. The square represents the risk difference for each study, the horizontal lines represent the values within the 95% confidence interval 8CI) of the underlying effects. The vertical line represents a risk difference of 0

Back to article page